Stammdaten
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Unternehmen & Branche
| Name | Armata Pharmaceuticals, Inc. |
|---|---|
| Ticker | ARMP |
| CIK | 0000921114 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 341,4 Mio. USD |
| Beta | 1,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -173,799,000 | -4.80 | 76,882,000 | -218,596,000 | |
| 2025-09-30 | 10-Q | -26,675,000 | -0.74 | 89,516,000 | -95,588,000 | |
| 2025-06-30 | 10-Q | -16,295,000 | -0.45 | 80,790,000 | -69,503,000 | |
| 2025-03-31 | 10-Q | -6,531,000 | -0.20 | 87,250,000 | -53,783,000 | |
| 2024-12-31 | 10-K | -18,916,000 | -0.89 | 86,437,000 | -48,019,000 | |
| 2024-09-30 | 10-Q | -5,481,000 | -0.15 | 98,237,000 | -50,973,000 | |
| 2024-06-30 | 10-Q | 8,986,000 | -0.25 | 108,313,000 | -46,101,000 | |
| 2024-03-31 | 10-Q | -25,021,000 | -0.69 | 120,356,000 | -56,510,000 | |
| 2023-12-31 | 10-K | -69,045,000 | -1.91 | 98,363,000 | -32,065,000 | |
| 2023-09-30 | 10-Q | -31,161,000 | -0.86 | 112,761,000 | -12,386,000 | |
| 2023-06-30 | 10-Q | -3,547,000 | -0.17 | 101,212,000 | 19,143,000 | |
| 2023-03-31 | 10-Q | -14,490,000 | -0.40 | 108,779,000 | 22,447,000 | |
| 2022-12-31 | 10-K | -36,917,000 | -1.08 | 95,834,000 | 36,080,000 | |
| 2022-09-30 | 10-Q | -8,614,000 | -0.24 | 92,881,000 | 45,577,000 | |
| 2022-06-30 | 10-Q | -9,215,000 | -0.26 | 100,984,000 | 53,291,000 | |
| 2022-03-31 | 10-Q | -8,774,000 | -0.30 | 107,765,000 | 61,539,000 | |
| 2021-12-31 | 10-K | -23,155,000 | -0.96 | 69,768,000 | 25,397,000 | |
| 2021-09-30 | 10-Q | -5,419,000 | -0.22 | 42,671,000 | 23,755,000 | |
| 2021-06-30 | 10-Q | -6,194,000 | -0.25 | 48,281,000 | 28,619,000 | |
| 2021-03-31 | 10-Q | -5,495,000 | -0.27 | 52,845,000 | 34,012,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.